Quantcast
Last updated on April 18, 2014 at 1:20 EDT

Biotech Firm Synedgen Announces Research Results Demonstrating Significant Antimicrobial Activity Against Food-borne Pathogens by its Lead Chitosan Derivative

July 16, 2011

Chitosan Derivatives Reduce E. coli and coliform concentrations in models of food contamination

(PRWEB) July 15, 2011

New research conducted jointly between Synedgen, Inc, and the School of Environment, Natural Resources and Geography, at Bangor University, Bangor, UK demonstrates that a novel biocompatible and bactericidal chitosan derivative developed by Synedgen offers a rapid and safe method to significantly reduce bacterial counts and inhibit pathogenic activity from dangerous disease causing pathogens such as E. coli and Salmonella. This derivative is formulated with chitosan acquired from shrimp shells, and appears to have a lasting effect that prevents both food spoilage and lowers the total numbers of tested pathogenic bacteria up to 3 days.

“Food-borne illness remains a serious health concern. This research confirms the ability of our biocompatible derivative to reduce lethal bacteria in food sources, and represents a new way of safely and effectively improving food safety as well as preventing food spoilage and contamination,” remarked Synedgen CEO Dr. William Wiesmann.

Bangor University Professor of Soil and Environmental Science Davey Jones stated, “This research strongly supports the potential of this product to dramatically reduce food-borne related illness, associated conditions, and death.”

According to the Centers for Disease Control and Prevention more than 300,000 people are hospitalized and 5,000 die as a result of food-borne illnesses each year in the United States. Prepackaged raw and cooked foods can pose a threat to consumer health due to the bacterial contamination that may occur during processing or preparation. Uncertainty regarding the source of food-borne illness increases consumer concerns about food safety, delays effective treatment and impedes food recall notices, as evidenced by the recent outbreak of E. coli in Europe, where the source of the outbreak initially remained elusive.

This research was presented at a poster session at the Society for Applied Microbiology (SfAM) Summer Conference on July 4 in Dublin, Ireland. The poster, Antibacterial action of chitosan-arginine against E. coli O157 in chicken juice, highlights the potential impact of Syndegen’s chitosan derivatives for use in the control of food-borne pathogens.

For the study, the researchers measured the antimicrobial action of the chitosan derivative in poultry juice contaminated with E. coli O157 under simulated refrigeration and room temperature storage conditions. Poultry juice was utilized because it reflects a typical environment in which E. coli multiplies, and is one of the major risk pathways for surface contamination and subsequent cross-contamination in the home.

The results demonstrate that the chitosan derivative caused significant reductions in pathogen cell counts, and this antimicrobial effect appeared to be immediate. The study also identified critical doses required to prevent pathogen proliferation under both refrigeration and room temperature conditions.

The research will be published in an upcoming article in the Journal of Food Control.

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. This platform technology provides the foundation for preventing bacterial growth and disruption of biofilms in human and environmental applications. Product development is targeted to specifically address unmet needs for therapies that treat and prevent infections, primarily from bacteria that have developed resistance to traditional antibiotics.

Synedgen’s Corporate Headquarters and Research Laboratories are in Claremont CA; Synedgen’s Manufacturing Facility is in Honolulu HI. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/7/prweb8641660.htm


Source: prweb